Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 28 June 2024, including: global CEO remuneration; another late-stage loss for Merck KGaA; deals shift to smaller M&A, partnering; Bayer AG’s Parkinson’s bets bear fruit; and India looks to innovate CAR-T models.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Titans Of Pharma: J&J Back On Top For CEO Remuneration" - Scrip, 25 June, 2024.)
(Also see "Merck KGaA Suffers Another Late-Stage Loss" - Scrip, 25 June, 2024.)
(Also see "Competitive Dealmaking Market Shifts To Smaller M&A, Partnering" - Scrip, 21 June, 2024.)
(Also see "Bayer's Bets In Parkinson's Start To Bear Fruit" - Scrip, 26 June, 2024.)
(Also see "As India Scales CAR-T Efforts, Can It Innovate Commercial Models?" - Scrip, 25 June, 2024.)
